Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Common Equity (2022 - 2025)

Dr Reddys Laboratories (RDY) has 3 years of Common Equity data on record, last reported at $3.4 billion in Q1 2024.

  • For Q1 2024, Common Equity rose 20.22% year-over-year to $3.4 billion; the TTM value through Mar 2024 reached $3.4 billion, up 20.22%, while the annual FY2024 figure was $3.4 billion, 17.71% up from the prior year.
  • Common Equity reached $3.4 billion in Q1 2024 per RDY's latest filing, up from $2.8 billion in the prior quarter.
  • Across five years, Common Equity topped out at $3.4 billion in Q1 2024 and bottomed at $2.5 billion in Q1 2022.
  • Average Common Equity over 3 years is $2.9 billion, with a median of $2.8 billion recorded in 2023.
  • Peak YoY movement for Common Equity: rose 10.9% in 2023, then grew 20.22% in 2024.
  • A 3-year view of Common Equity shows it stood at $2.5 billion in 2022, then rose by 10.9% to $2.8 billion in 2023, then increased by 20.22% to $3.4 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Common Equity were $3.4 billion in Q1 2024, $2.8 billion in Q1 2023, and $2.5 billion in Q1 2022.